脑转移瘤立体定向放射治疗进展

MRI在脑转移瘤的诊断、治疗以及随访中有重要作用。原发灶状况、脑转移瘤的体积、立体定向放疗前后是否加全脑放疗、一般状况评分、回归分割分析(RPA)分级、是否存在颅外转移等是影响脑转移瘤治疗效果的主要因素。单纯立体定向放疗逐渐成为脑转移瘤治疗的主流．分次立体定向放疗在脑转移瘤治疗中的作用尚未完全明确。     

多发性脑转移瘤的立体定向伽玛刀治疗

多发性脑转移瘤(multiple brain metastasis，MBM)由于瘤体散在、多发，成为神经外科疾病治疗难点，近年来，随着立体定向伽玛刀治疗技术的广泛应用，其逐渐成为MBM的首选治疗方法。本主要对立体定向伽玛刀治疗MBM的机制、预后因素及治疗新进展进行综述。     

多发性脑转移瘤的立体定向伽玛刀治疗

多发性脑转移瘤(multiple brain metastasis,MBM)由于瘤体散在、多发,成为神经外科疾病治疗难点,近年来,随着立体定向伽玛刀治疗技术的广泛应用,其逐渐成为MBM的首选治疗方法。本文主要对立体定向伽玛刀治疗MBM的机制、预后因素及治疗新进展进行综述。     

脑转移瘤立体定向放射治疗进展

MRI在脑转移瘤的诊断、治疗以及随访中有重要作用。原发灶状况、脑转移瘤的体积、立体定向放疗前后是否加全脑放疗、一般状况评分、回归分割分析(RPA)分级、是否存在颅外转移等是影响脑转移瘤治疗效果的主要因素。单纯立体定向放疗逐渐成为脑转移瘤治疗的主流,分次立体定向放疗在脑转移瘤治疗中的作用尚未完全明确。     

难治性脑转移瘤的立体定向放射外科治疗策略及进展

脑转移瘤是发病率高、临床治疗难度大且预后较差的颅内常见恶性疾病,特别是其中的难治性脑转移瘤(大体积、多发、复发的转移瘤)常规治疗难以达到理想预后.立体定向放射外科(SRS)与常规治疗方式相比具有精准度高、单次照射剂量大、对周围组织损伤低等优势,已逐渐成为脑转移瘤患者治疗的首选方案.SRS治疗难治性脑转移瘤具有较好的效果...     

脑转移瘤的立体定向放射治疗

立体定向放射（ＳＲＴ）已历时４０余年，取得的成绩较常规外照射是显著的。脑转移癌的占尸检癌症病人的１０％￣２０％，对该病的治疗同原发脑瘤有许多不同之处。本文着重就脑转移瘤的ＳＲＴ的治疗进展情况作一综述，以期在病人的选择，放疗剂量，靶区的规划以及预后因素的分析等方面做一探讨。     

立体定向放射治疗脑转移瘤疗效分析

目的 分析立体定向放射疗法(SRT)治疗脑转移瘤的临床疗效。方法 回顾性分析66例脑转移瘤全脑放射治疗(WBRT)追加SRT和26例脑转移瘤单纯SRT的结果,分析两者在Karnofsky评分、颅内肿瘤复发率、一年生存率等方面的状况。结果 WBRT+SRT组在颅内肿瘤复发率(13.3%和42.2%)、中位复发时间(10.5个月和4.2个月)、中位生存期(13.0个月和6.5个月)与单纯SRT组相比有显著性差异(P<0.05),但在Karnofsky评分、治疗有效率、一年生存率、死亡率的差异均无统计学意义。结论 WBRT+SRT能明显改善患者的生存质量,降低肿瘤颅内复发率,是脑转移瘤的一种理想局部治疗手段。     

脑转移瘤γ刀、X刀治疗后MRI观察与分析

目的　利用MRI评价立体定向放射外科治疗脑转移瘤的疗效。方法　选择 70例经γ刀、X刀治疗后的MRI复查资料进行分析治疗后的影像表现。结果　经γ刀、X刀治疗后肿瘤控制率在 91%,消失率在 5 8%,肿瘤消失缩小 ,肿瘤强化程度减低 ,病灶中间出现坏死 ,环状强化是疗效满意的征像。肿瘤增大 ,水肿增大 ,先小后大 ,出现新病灶是复发的征像。结论　脑转移瘤立体定向放射外科治疗后应用MRI能客观评价治疗效果     

脑转移瘤X刀治疗31例临床报告

目的：提高Ｘ刀治疗脑转移瘤的认识。方法：用Ｘ刀治疗脑转移瘤３１ 例并随访２～２４月,其中单发病灶１４例,多发病灶１７例。共７２ 个病灶。结果：脑转移瘤较小者,完全缓解率高,较大者（＞ ４ ｃｍ ）经分次治疗也有较高的缓解率。结论：单发病灶经Ｘ刀治疗后半年,１年存活率高。对多发病灶更显优越。需配合全脑放疗及化疗。否则易产生新病灶。     

脑动静脉畸形的X刀治疗

目的　探讨立体定向放射外科治疗脑动静脉畸形的临床效果。方法　对 87例脑动静脉畸形患者采用X刀治疗 ,畸形团大小大小 5～ 4 0mm。单独接受X刀治疗 5 5例 ,联合血管内栓塞治疗32例。治疗周边剂量 17～ 30Gy ,平均 2 2 .6Gy ,等剂量曲线 70 %～ 90 %。随访时间 6～ 96个月 ,平均 5 3.4个月。结果　单独应用X刀治疗的脑动静脉畸形患者 ,完全闭塞 4 1例 ,部分闭塞 9例 ,无变化 5例 ;联合血管内栓塞治疗患者 ,完全闭塞 2 6例 ,部分闭塞 3例 ,无变化 3例。全组完全闭塞 6 7例 (77.0 % )。癫痫完全缓解 7例 (2 6 .2 % ) ,头痛头昏症状缓解 18例 (38.3% )。并发症 :再出血 2例 ,症状性放射性脑水肿 6例 ,经治疗后 ,完全缓解 2例 ,遗留神经功能障碍 4例。结论　立体定向放射外科是脑动静脉畸形的安全而有效的治疗方法之一。     

Plan quality comparison between 4-arc and 6-arc noncoplanar volumetric modulated arc stereotactic radiotherapy for the treatment of multiple brain metastases

To compare the plans of 4-arc and 6-arc noncoplanar volumetric modulated arc stereotactic radiotherapy (VMA-SRT) for multiple brain metastases and to investigate the cutoff value for the tumor number and volume for 6-arc rather than 4-arc VMA-SRT. We identified 24 consecutive multiple-target cases (3 to 19 targets in each case) with 189 total targets. We constructed plans using both 4- and 6-arc noncoplanar VMA-SRT. The prescribed dose was 36?Gy/6 fr, and it was delivered to 95% of the planning target volume (PTV). The plans were evaluated for the dose conformity using the Radiation Therapy Oncology Group and Paddick conformity indices (RCI and PCI), fall-off (Paddick gradient index [PGI]), and the normal brain dose. The median (range) RCI, PCI, and PGI was 0.94 (0.92 to 0.99), 0.89 (0.77 to 0.94), and 3.75 (2.24 to 6.54) for the 4-arc plan and 0.94 (0.91 to 0.98), 0.89 (0.76 to 0.94), and 3.65 (2.24 to 6.5) for the 6-arc plan, respectively. The median (range) of the normal brain dose was 910.3 cGy (381.4 to 1268.9) for the 4-arc plan and 898.8 cGy (377 to 1252.9) for the 6-arc plan. The PGI of the 6-arc plan was significantly superior to that of the 4-arc plan (p?=?0.0076), and the optimal cutoff values for the tumor number and volume indicative of 6-arc (and not 4-arc) VMA-SRT were cases with ≥ 5 metastases and a PTV of ≥ 12.9?mL, respectively. The PCI values, however, showed no significant difference between the 2 plans. We believe these results will help in considering the use of 6-arc VMA-SRT for multiple brain metastases.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.     

立体定向分次放疗联合全脑放射治疗脑转移瘤疗效分析

Objective To evaluate efficiency of brain metastases tumor using X-knife under farctionational stereotactie radiotherapy (FSRT) combine with whole brain radiotherapy (WBRT). Methods Retrospective comparing 51 patients treated by FSRT plus WBRT (FSRT + WBRT group) with 35 patients treated by WBRT alone (WBRT group) on the effecting rate and survival rate. Results The completeness response rate was 49 % and 26 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. The effecting rate was 80 % and 71 % (P 0.05) in FSRT + WBRT and WBRT groups, respectively. The middle survival time was (11.0 ± 1.5) months and (6.5 ± 0.5) months (P < 0.05) in FSRT + WBRT and WBRT groups, respeetivley. The 0.5-, 1.0- and 1.5-years survival rate was 63 % and 41 % (P 0.05), 51 % and 23 % (P 0.05) and 24 % and 9 % (P < 0.05) in FSRT + WBRT and WBRT groups, respectively. Conclusions The method with FSRT plus WBRT in the treatment of brain metastases tumor is safe and relieved focal symptom of patients quickly with lesser injury on normal tissue and the survival time be prolonged, it has better therapeutic effects than WBRT alone for treating brain metastases tumor.